Pharma's Almanac TVPA TV
 
  • Follow the Journey
  • Companies We've Met
  • AES Clean Technology
  • Altis Biosystems
  • Arranta Bio
  • Avara Pharmaceutical Services
  • Avid Bioservices
  • BioVectra
  • Centaur BPS
  • Dynamk Capital
  • ECRI
  • Evolve Biologics
  • Federal Equipment Company
  • Globyz
  • Inceptor Bio
  • IPS-Integrated Project Services
  • Olon
  • Pii
  • Polpharma Biologics
  • PPD
  • RoosterBio
  • SanaClis
  • Sanofi AIS
  • SGD Pharma
  • SPI Pharma
  • TriRx Pharmaceutical Services
  • Yourway
Dashboard
Your Name
Your Email
  • Manage Account
  • Sign Out
Sign In
Register
    • Topics
        Products
        • ADC
        • API - Small Molecule
        • Biologics
        • Biopharmaceuticals
        • Biosimilars
        • Cell and Gene Therapy
        • DNA
        • Drug Product
        • Drug Substance
        • Equipment
        • Generics
        • Immunotherapy
        • Injectables
        • Monoclonal Antibody
        • Novel Therapeutics
        • Oral Solid Dosage
        • Orphan Drugs
        • Parenterals
        • Stem Cells
        • Vaccine
        Services
        • Big Data
        • Bioprocessing
        • Clinical Trials
        • Continuous Manufacturing
        • Diagnostics
        • Drug Delivery
        • Drug Development
        • Drug Discovery
        • Facility
        • Formulation
        • Innovation
        • Oncology
        • Patient Adherence
        • Patient Centric
        • Preclinical
        • Process Development
        • Quality
        • Regulatory
        • Research
        • Serialization
        Segment
        • Biomanufacturing
        • Biotechnology
        • CDMO
        • Consulting
        • CRO
        • Engineering
        • Equipment
        • Excipients
        • Healthcare
        • Intermediates
        • Logistics
        • Manufacturing
        • Packaging
        • Supply Chain
        Business
        • Agreement
        • Appointment
        • Business
        • Capacity Expansion
        • Collaboration
        • Growth
        • Investment
        • Licensing
        • M&A
        • Market Expansion
        • Market Intelligence
        • Market Prediction
        • New Facility
        • Strategic Partnership
    • Magazine
      • Current Issue
      • Archive
    • Reports
      • Biologics Pricing Report
      • Oral Solid Dose Market Report
    • Community
    • Company A to Z
    • Content Filter
    • More+
      • Staffing
      • Media Kit
      • By The Numbers

    Atopic Dermatitis

    6 Articles Available

    Can't find what you're looking for? Try our advanced search.

    Licensing

    LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate
    PR-M04-20-NI-023

    Phase III

    Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib for Moderate to Severe Atopic Dermatitis
    PR-M09-19-NI-001

    Pfizer Announces Positive Top-Line Results from Phase 3 Study in Patients with Moderate to Severe Atopic Dermatitis
    PR-M05-19-NI-055

    Clinical Trials

    AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
    PR-M03-19-NI-022

    Phase 2 Study

    Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
    PR-M05-18-NI-107

    Positive Trial

    Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
    PR-M05-18-NI-072

    About Us
    That’s Nice Staffing By The Numbers
    More
    Media Kit Download Current Issue
    Your Account
    Manage Your Account Dashboard Sign Out
    Sign In Register
    Help
    Contact Us Support
    Nice Insight/That’s Nice

    89 Fifth Avenue
    Fifth Floor
    New York
    NY 10003-3020

    New York – San Diego – Chicago
    London – Frankfurt – Shanghai

    Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.

    © PHARMA’S ALMANAC 2021 Terms and Conditions